首页> 外文期刊>Oncology Research >Aberrant lncRNA Expression in Multiple Myeloma
【24h】

Aberrant lncRNA Expression in Multiple Myeloma

机译:多种骨髓瘤中的异常lncrna表达

获取原文
获取原文并翻译 | 示例
       

摘要

Multiple myeloma (MM), a type of malignant tumor, is characterized by dysplasia of clonal plasma cells in the bone marrow. People with MM will have damaged organs or tissues due to secretion of large amounts of monoclonal immunoglobulin or fragments (M protein). Despite improved survivability by novel treatment strategies over the last decade, MM is still incurable by current therapies. Long noncoding RNAs (lncRNAs), with length of more than 200 nucleotides, have been reported to act as important regulators in many diseases, including MM. Recent studies have reported aberrant lncRNA expression in MM; these dysregulated lncRNAs can play oncogenic and/or tumor-suppressive roles in the development and progression of MM. In this article, we present a general overview on the role of lncRNAs in MM pathogenesis and discuss their potential as prognostic biomarkers and targets for treatment.
机译:多发性骨髓瘤(mm)是一种恶性肿瘤,其特征在于骨髓中克隆血浆细胞的发育不良。 由于大量单克隆免疫球蛋白或片段(M蛋白)的分泌,MM的人们会受到损伤的器官或组织。 尽管在过去十年的新型治疗策略提高了生存能力,但MM仍然可以通过当前疗法来抵抗。 据报道,长度不划分的RNA(LNCRNA)长度超过200个核苷酸,以在许多疾病中作为重要调节剂,包括MM。 最近的研究报告了MM中的异常LNCRNA表达; 这些失去的LNCRNA可以在MM的开发和进展中发挥致癌和/或肿瘤抑制作用。 在本文中,我们概述了LNCRNA在MM发病机制中的作用的概述,并讨论其作为预后生物标志物和治疗目标的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号